期刊
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
卷 2021, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2021/6653790
关键词
-
类别
资金
- Charles B. Hammond Research Fund, School of Medicine, Duke University, Durham, North Carolina, USA
- NIH/NCI Duke Comprehensive Cancer Center Core Grant [5-P30-CA014236-47]
- BioMimetix JV, LLC
- China Scholarship Council
MnPs were initially developed as SOD mimics but later found to react with various reactive species and modify protein activities through oxidation, affecting both normal and cancer cells. Lead Mn porphyrins have been tested in various injury and cancer models, with some progressing to clinical trials for glioma, head and neck cancer, anal cancer, and other conditions.
Mn(III) ortho-N-alkyl- and N-alkoxyalkyl porphyrins (MnPs) were initially developed as superoxide dismutase (SOD) mimics. These compounds were later shown to react with numerous reactive species (such as ONOO-, H2O2, H2S, CO3 center dot-, ascorbate, and GSH). Moreover, the ability of MnPs to oxidatively modify activities of numerous proteins has emerged as their major mechanism of action both in normal and in cancer cells. Among those proteins are transcription factors (NF-kappa B and Nrf2), mitogen-activated protein kinases, MAPKs, antiapoptotic bcl-2, and endogenous antioxidative defenses. The lead Mn porphyrins, namely, MnTE-2-PyP5+ (BMX-010, AEOL10113), MnTnBuOE-2-PyP5+ (BMX-001), and MnTnHex-2-PyP5+, were tested in numerous injuries of normal tissue and cellular and animal cancer models. The wealth of the data led to the progression of MnTnBuOE-2-PyP5+ into four Phase II clinical trials on glioma, head and neck cancer, anal cancer, and multiple brain metastases, while MnTE-2-PyP5+ is in Phase II clinical trial on atopic dermatitis and itch.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据